Zuyuan Lin

531 total citations
29 papers, 326 citations indexed

About

Zuyuan Lin is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Zuyuan Lin has authored 29 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hepatology, 12 papers in Epidemiology and 11 papers in Molecular Biology. Recurrent topics in Zuyuan Lin's work include Liver Disease Diagnosis and Treatment (9 papers), Organ Transplantation Techniques and Outcomes (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Zuyuan Lin is often cited by papers focused on Liver Disease Diagnosis and Treatment (9 papers), Organ Transplantation Techniques and Outcomes (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Zuyuan Lin collaborates with scholars based in China, Madagascar and United States. Zuyuan Lin's co-authors include Di Lu, Xiao Xu, Modan Yang, Jianyong Zhuo, Xuyong Wei, Xinyu Yang, Shusen Zheng, Xinyu Yang, Haiyang Xie and Jianguo Wang and has published in prestigious journals such as Free Radical Biology and Medicine, Frontiers in Immunology and Cell Death and Disease.

In The Last Decade

Zuyuan Lin

25 papers receiving 322 citations

Peers

Zuyuan Lin
Zuyuan Lin
Citations per year, relative to Zuyuan Lin Zuyuan Lin (= 1×) peers Modan Yang

Countries citing papers authored by Zuyuan Lin

Since Specialization
Citations

This map shows the geographic impact of Zuyuan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zuyuan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zuyuan Lin more than expected).

Fields of papers citing papers by Zuyuan Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zuyuan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zuyuan Lin. The network helps show where Zuyuan Lin may publish in the future.

Co-authorship network of co-authors of Zuyuan Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Zuyuan Lin. A scholar is included among the top collaborators of Zuyuan Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zuyuan Lin. Zuyuan Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Jinyan, Zhigang Hu, Zuyuan Lin, et al.. (2025). Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia. BMC Cancer. 25(1). 1565–1565.
2.
Lu, Di, Abid Khan, Qingguo Xu, et al.. (2024). Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma. Journal of Cachexia Sarcopenia and Muscle. 15(5). 2071–2083. 6 indexed citations
3.
Chen, Jinyan, Jianyong Zhuo, Zuyuan Lin, et al.. (2024). Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma. Cancer Biology and Medicine. 21(11). 1033–1049. 3 indexed citations
4.
Lin, Zuyuan, Hao Chen, Chenghao Cao, et al.. (2024). Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis. BMC Cancer. 24(1). 1042–1042. 1 indexed citations
5.
Lin, Zuyuan, Mengfan Yang, Binhua Pan, et al.. (2024). Evaluation of liver regeneration after hemi-hepatectomy by combining computed tomography and post-operative liver function. Heliyon. 10(10). e30964–e30964.
6.
Zhuo, Jianyong, Peiru Zhang, Wei Feng Shen, et al.. (2024). Growth differentiation factor 7 alleviates the proliferation and metastasis of hepatocellular carcinoma. Liver Research. 8(4). 259–268.
7.
Lu, Di, Jingyan Chen, Jianyong Zhuo, et al.. (2024). Post-transplant hepatitis B virus reactivation impacts the prognosis of patients with hepatitis B-related hepatocellular carcinoma: a dual-centre retrospective cohort study in China. International Journal of Surgery. 110(4). 2263–2274. 2 indexed citations
8.
Lin, Zuyuan, Jianyong Zhuo, Modan Yang, et al.. (2023). TNFR2 is a potent prognostic biomarker for post-transplant lung metastasis in patients with hepatocellular carcinoma. Chinese Journal of Cancer Research. 35(1). 66–80. 7 indexed citations
9.
Lin, Zuyuan, Modan Yang, Hao Chen, et al.. (2023). Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma. Frontiers in Oncology. 13. 1072775–1072775. 9 indexed citations
10.
Yang, Modan, et al.. (2023). FGF21-mediated autophagy: Remodeling the homeostasis in response to stress in liver diseases. Genes & Diseases. 11(3). 101027–101027. 8 indexed citations
11.
Yang, Modan, Hao Chen, Zuyuan Lin, et al.. (2023). Double-negative T cells: a promising avenue of adoptive cell therapy in transplant oncology. Journal of Zhejiang University SCIENCE B. 24(5). 387–396. 3 indexed citations
12.
Lu, Di, Xinyu Yang, Zhengxing Lian, et al.. (2023). Dynamic immune cell profiling identified natural killer cell shift as the key event in early allograft dysfunction after liver transplantation. Cell Proliferation. 57(4). e13568–e13568. 5 indexed citations
13.
Lu, Di, Zuyuan Lin, Rui Wang, et al.. (2022). Multi-omics profiling reveals Chitinase-3-like protein 1 as a key mediator in the crosstalk between sarcopenia and liver cancer. Redox Biology. 58. 102538–102538. 23 indexed citations
14.
Lin, Zuyuan, Hao Chen, Xinyu Yang, et al.. (2022). Liver Organoids, Novel and Promising Modalities for Exploring and Repairing Liver Injury. Stem Cell Reviews and Reports. 19(2). 345–357. 14 indexed citations
15.
Lu, Di, et al.. (2022). One Shoot, Two Birds: Alleviating Inflammation Caused by Ischemia/Reperfusion Injury to Reduce the Recurrence of Hepatocellular Carcinoma. Frontiers in Immunology. 13. 879552–879552. 17 indexed citations
16.
Zhuo, Jianyong, Di Lu, Zuyuan Lin, et al.. (2021). The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib. Cell Death and Disease. 12(12). 1084–1084. 26 indexed citations
17.
Zhang, Chenzhi, Xuyong Wei, Rongli Wei, et al.. (2021). NEAT1/hsa-miR-372–3p axis participates in rapamycin-induced lipid metabolic disorder. Free Radical Biology and Medicine. 167. 1–11. 12 indexed citations
18.
Zhuo, Jianyong, Di Lu, Zuyuan Lin, et al.. (2020). C C motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells. Hepatobiliary & pancreatic diseases international. 19(5). 440–448. 13 indexed citations
19.
Yang, Xinyu, Di Lu, Jianyong Zhuo, et al.. (2020). The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases. International Journal of Biological Sciences. 16(13). 2357–2366. 78 indexed citations
20.
Lu, Di, Fan Yang, Zuyuan Lin, et al.. (2019). A prognostic fingerprint in liver transplantation for hepatocellular carcinoma based on plasma metabolomics profiling. European Journal of Surgical Oncology. 45(12). 2347–2352. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026